You just read:

Ascentage Pharma's Core Drug Candidate HQP1351 Granted Orphan Drug Designation by the US FDA for the Treatment of Patients with Chronic Myeloid Leukemia

News provided by

Ascentage Pharma

May 04, 2020, 06:30 ET